SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. The firm offers annealing and gate-model quantum computing technologies. It provides professional services that assist customers in identifying and implementing quantum computing applications and selling quantum computer systems to customers. The company was founded by Eric Ladizinsky in 1999 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

QBTS is drawing attention amid a sharp selloff and repeated lows, with traders citing weakness across quantum stocks and concerns about high valuations, losses, and the long path to commercial adoption. Some see the decline as a buying opportunity and point to D-Waves deployments and partnerships, while others remain skeptical that near-term business progress can support the valuation.

ExxonMobil Holdings Corp. is an international energy and petrochemical company, which creates solutions that improve quality of life and meets society’s evolving needs. The company is headquartered in Spring, TX.

ExxonMobil Holdings Corp.

Exxon Mobil Corp

Exxons third-quarter results beat expectations, with strong refining profits and record operating performancesupported by elevated fuel margins amid supply disruptionsdriving the shares higher. Traders welcomed the results and shareholder-return plans, though some noted the stocks modest reaction and bearish put-heavy options activity.

Charter Communications, Inc. engages in providing broadband communications services. Its services include Spectrum TV, Spectrum Internet, and Spectrum Voice. It offers business-to-business Internet access, data networking, business telephone, video and music entertainment services, and wireless backhaul. Its advertising sales division, Spectrum Reach, offers local, regional, and national businesses the opportunity to advertise in individual and multiple service areas on cable television networks and advanced advertising platforms. The company was founded in 1993 and is headquartered in Stamford, CT.

Charter Communications Inc. - Ordinary Shares - Class A

Attention centers on Charters upcoming earnings and whether it can arrest broadband subscriber losses amid fiber, fixed-wireless and satellite competition, while managing its substantial debt. Bulls point to the depressed valuation, mobile growth and potential cash-flow recovery; bears see ongoing customer losses and weak fundamentals as reasons for continued caution.

Dutch Bros, Inc. engages in operating and franchising drive-thru shops that focus on handcrafted beverages. It operates through the Company-Operated Shops, and Franchising and Other segments. The Company-Operated Shops segment consists of coffee shop sales to customers. The Franchising and Other segment is involved in bean and product sales to franchisees and includes the initial franchise fees, royalties, and marketing fees. The company was founded by Travis Boersma and Dane Boersma in 1992 and is headquartered in Tempe, AZ.

Dutch Bros Inc - Ordinary Shares - Class A

Dutch Bros Inc

A steep selloff and repeated 52-week lows are driving attention, with traders debating whether the decline reflects a still-rich valuation and concerns about consumer spending, costs, and competition. Bulls see the shares as oversold and emphasize Dutch Bros growth, while bears expect more downside.

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.

Mineralys Therapeutics Inc

Shares are under pressure as traders react to weak early sales for AstraZenecas competing hypertension drug, Baxfendy, and limited insurance coverage, fueling doubts about lorundrostats commercial prospects. Some investors argue the launch is still in an early coverage ramp and see upcoming data and the FDA decision as important milestones; others worry Mineralys may struggle to compete on its own.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

A sharp breakout to fresh 52-week highs has drawn attention as traders position ahead of an expected Q3 report and watch BRIUMVIs commercial ramp. Buyout and short-squeeze speculation is prominent, though others see the move as momentum into earnings rather than evidence of a deal.

Nu Holdings Ltd. is a holding company, which engages in the provision of digital banking services. The company was founded by David Vélez Osorno, Cristina Helena Zingaretti Junqueira, and Adam Edward Wible on February 26, 2016 and is headquartered in São Paulo, Brazil.

Nu Holdings Ltd - Ordinary Shares Class A

Nu Holdings Ltd

Brazilian equities sold off sharply after Lulas reelection, weighing on NU as traders reassessed political and macroeconomic risks in its core market. The community is divided between viewing the drop as an overreaction to the election, with the business fundamentals intact, and worrying that Brazil-related risks could prolong the weakness.

ON Semiconductor Corp. engages in the provision of intelligent power and sensing solutions with a primary focus on automotive and industrial markets. It operates through the following segments: Power Solutions Group (PSG), Analog and Mixed-Signal Group (AMG), and Intelligent Sensing Group (ISG). The PSG segment offers discrete, module, and integrated semiconductor products that perform multiple application functions, including power switching, signal conditioning, and circuit protection. The AMG segment designs and develops analog, mixed-signal, power management integrated circuits, sensor interface devices, power conversion, signal chain, and voltage regulation devices. The ISG focuses on the design and development of complementary metal oxide semiconductor image sensors, image signal processors, single photon detectors, including silicon photomultipliers, single photon avalanche diode arrays, and short-wavelength infrared products, as well as actuator drivers for autofocus and image stabilization. The company was founded on July 4, 1999 and is headquartered in Scottsdale, AZ.

ON Semiconductor Corp.

Traders are weighing growth in onsemis Other end-market bucket, which includes computing and AI data-center demand, against concerns that long-term supply agreements can be changed or canceled. The discussion is split between buyers viewing the pullback as an opportunity and skeptics pointing to weak auto and industrial demand and questioning how durable the AI-related growth will be.

Delta Air Lines, Inc. engages in the provision of scheduled air transportation for passengers and cargo. It operates through the Airline and Refinery segments. The Airline segment provides scheduled air transportation for passengers and cargo. The Refinery segment provides jet fuel to the airline segment. The company was founded by Collett Everman Woolman in 1928 and is headquartered in Atlanta, GA.

Delta Air Lines, Inc.

Deltas quarterly earnings miss and reduced profit outlook, driven by sharply higher fuel costs, are the main focus. Traders are split between concern that fuel and operating expenses will squeeze margins and optimism that resilient travel demand, premium revenue, and fare increases can offset the pressure.

Air Canada engages in the provision of airline transportation services. Its services cover full-service airline, scheduled passenger and cargo services, serving more than two hundred airports on six continents. It operates through the following geographical segments: Canada, U.S. Transborder, Atlantic, Pacific, and Other. The company was founded on April 11, 1936 and is headquartered in Saint-Laurent, Canada.

Air Canada Inc. - Ordinary Shares (Voting and Variable Voting)

Air Canada Inc.

Air Canadas earnings and outlook are driving the discussion, with traders focused on elevated jet-fuel costs and reduced guidance as the shares fall. Some see strong revenue, resilient demand, buybacks and Aeroplans value as support, while others worry fuel pressure will weigh on profitability.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

KOD Stock Cracks September’s Top 5 Biotech Gainers On Eye Drug Win — But ‘Pharma Bro’ Shkreli Says It ‘Still Sucks’ 

Equity

Martin Shkreli, who said he was short KOD before the readout, questioned Zenkuda’s edge over Eylea and dismissed the added IL-6 targeting in KSI-501.

MRNA On Track To Be September's No. 2 S&P 500 Stock — But These 5 Smaller Health Care Names Did Even Better

Five smaller stocks with market caps above $100 million beat MRNA’s monthly gain: INDP rose 249%, CYPH 124%, MNOV 85%, GRAL 58% and SRZN 53%.

12 Health Care Stocks Moving In Tuesday's Intraday Session

Gainers

Indaptus Therapeutics (NASDAQ:INDP) stock increased by 46.7% to $1.79 during Tuesday's regular session. The market value of their outstanding shares is at $162.5 million.
PDS Biotechnology (NASDAQ:PDSB)read more...

12 Health Care Stocks Moving In Thursday's Intraday Session

Gainers

Indaptus Therapeutics (NASDAQ:INDP) shares moved upwards by 34.0% to $1.26 during Thursday's regular session. The company's market cap stands at $125.2 million.
BioVie (NASDAQ:BIVI) stock rose 30.85%read more...

Why Did INDP Stock Gain 12% Today?

The company has secured a $6 million investment from investor David E. Lazar via the sale of non-voting convertible preferred stock. 


What Does the Market Think About Indaptus Therapeutics Inc?

Biotech Stocks To Keep An Eye On - December 24th

Abivax, Indaptus Therapeutics, Danaher, Vertex Pharmaceuticals, Moderna, argenex, and Amicus Therapeutics are the seven Biotech stocks to watch today, according to MarketBeat's stock screener tool...

Indaptus Therapeutics, Uipath, Trinity Biotech, Sable Offshore And McDonald's: Why These 5 Stocks Are On Investors' Radars Today

INDP, PATH, TRIB, SOC, MCD were among the stocks seen among investors on Tuesday, Dec. 23, 2025.read more...

Indaptus Therapeutics, Inc. is a clinical biotechnology company. The firm engages in the development of a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It created patented treatment methods and associated patented compositions for attenuation and killing of non-pathogenic, Gram-negative bacteria. The company was founded by Michael James Newman on February 24, 2021 and is headquartered in New York, NY.

Indaptus Therapeutics Inc

Neutral Sentiment

<ul class="summary-bullets"><li><a class="mention" data-mention="$KOD" data-symbol-id="KOD" href="https://stocktwits.com/symbol/KOD" target="_blank">KOD</a> surged 178% Monday to $89.92, its best day on record and highest close since December 2021.</li><li>Kodiak said its separate eye drugs Zenkuda and KSI-501 met the primary endpoints in the Phase 3 Daybreak trial against the active ingredient in original Eylea.</li><li>Jefferies raised its <a class="mention" data-mention="$KOD" data-symbol-id="KOD" href="https://stocktwits.com/symbol/KOD" target="_blank">KOD</a> price target to $112, implying about 25% upside from Monday’s close. LifeSci Capital’s $145 target implies 61% upside, while H.C. Wainwright’s $96 target implies 7%.</li></ul>Shares of Kodiak Sciences (<a class="mention" data-mention="$KOD" data-symbol-id="KOD" href="https://stocktwits.com/symbol/KOD" target="_blank">KOD</a>) broke into September’s top five biotech gainers on a key eye drug win. Still, investor Martin Shkreli questioned whether it can outshine Eylea, Regeneron’s established treatment for wet age-related macular degeneration (AMD).<a href="https://stocktwits.com/symbol/KOD">KOD stock</a> soared 178% on Monday to $89.92, logging its best day on record and closing at its highest level since December 2021. The rally lifted its September gain to 141%, behind only PDS Biotechnology (PDSB), up 258%, and Indaptus Therapeutics (INDP), up 187%, among biotech stocks.&nbsp;With PDSB valued at less than $50 million, Kodiak trailed only Indaptus among biotech companies worth more than $100 million. It outperformed GRAIL (GRAL), up 67% this month; Moderna (MRNA), up 41%; and Iovance Biotherapeutics (IOVA), up 35%.<img src="https://news.stocktwits-cdn.com/kod_biotech_0e2c321288.png" alt="kod biotech.png"><h2 class="st-heading-2">Daybreak Delivers A Double Win For <a class="mention" data-mention="$KOD" data-symbol-id="KOD" href="https://stocktwits.com/symbol/KOD" target="_blank">KOD</a> Stock</h2>Kodiak said on Monday that two separate experimental drugs, Zenkuda and KSI-501, met the primary endpoints in its Phase 3 Daybreak trial. Each produced vision gains that were non-inferior to those achieved with 2-milligram Aflibercept, the active ingredient in Regeneron’s (REGN) original Eylea.&nbsp;<img src="https://news.stocktwits-cdn.com/record_rally_kod_da4ae67085.png" alt="record rally kod.png">Zenkuda targets VEGF, a protein involved in the abnormal blood vessel growth seen in wet AMD. Kodiak said that 54% of Zenkuda patients reached a 24-week dosing interval at one year under criteria that called for retreatment when retinal fluid appeared. The company also reported no intraocular inflammation in the Zenkuda arm. It plans to file for approval in the fourth quarter using data from five positive Phase 3 studies across three eye conditions.<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.kodiak.com/news-releases/news-release-details/zenkuda-and-tabirafusp-ted-meet-primary-endpoints-pivotal?utm_source=chatgpt.com">&nbsp;</a>KSI-501, also called Tabirafusp-ted, is a different drug. It targets both VEGF and IL-6, a protein associated with inflammation. It met Daybreak’s vision endpoint and a key retinal anatomy endpoint. Kodiak plans further analyses to see whether particular wet AMD patients benefit from the added IL-6 targeting, while a separate Phase 3 trial is studying KSI-501 in diabetic macular edema.<h2 class="st-heading-2">Shkreli Pushes Back On Kodiak’s Win&nbsp;</h2>Shkreli&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/MartinShkreli/status/2104520450999284092">congratulated</a> Kodiak on meeting both primary endpoints, but called for the numerical vision results against Eylea and pointed to competition from Eylea biosimilars. He had said last week that he was&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/MartinShkreli/status/2103521047639171529">short KOD</a> ahead of the readout and predicted that the stock would fall.&nbsp;When another investor praised Zenkuda’s six-month dosing and suggested Kodiak could become a takeover target, Shkreli<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/MartinShkreli/status/2104705935717335382">&nbsp;asked</a>: “How do you know you can't get the same out of Eylea? presumably vastly cheaper”In a&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/MartinShkreli/status/2104705348976415050">separate post</a>, he said that “the drug still sucks,” called the formulation change “just an extra loading dose” and argued that Zenkuda’s numerical vision result was worse. He had also<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/MartinShkreli/status/2104363503456813292">&nbsp;questioned</a> whether the formulation changes could improve efficacy. Shkreli’s criticism extended to KSI-501. He<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/MartinShkreli/status/2104554538925482159">&nbsp;argued</a> that its IL-6 targeting offered no benefit beyond Zenkuda’s VEGF targeting.&nbsp;The FDA has approved interchangeable biosimilars to original Eylea, adding competition for its 2-milligram formulation. Meanwhile, Regeneron's separate Eylea HD has an approved dosing interval of up to 20 weeks for eligible wet AMD patients.&nbsp;<h2 class="st-heading-2">Wall Street Lifts <a class="mention" data-mention="$KOD" data-symbol-id="KOD" href="https://stocktwits.com/symbol/KOD" target="_blank">KOD</a> Targets After Daybreak Win</h2>Analysts responded to Daybreak with steep price target increases. Jefferies raised its Kodiak target to $112 from $56, maintained its ‘Buy’ rating and called the Zenkuda outcome a “slam dunk.” It lifted its estimated probability of success to 80% from 65% and its peak sales forecast to $1.8 billion from $400 million.LifeSci Capital raised its target to $145 from $85 and kept its ‘Outperform’ rating, calling Eylea-like efficacy paired with differentiated durability as a “best-case scenario outcome.” H.C. Wainwright lifted its target to $96 from $58, maintained its ‘Buy’ rating and singled out Zenkuda’s rapid and sustained retinal drying as “highly compelling.”Evercore ISI said that the initial release “reads excellent,” while seeking more detail beyond the topline announcement. Citi said Kodiak’s data raised the longer-term competitive bar for Regeneron, but pointed to Eylea HD’s broad label, physician familiarity, and momentum with patients.Based on <a class="mention" data-mention="$KOD" data-symbol-id="KOD" href="https://stocktwits.com/symbol/KOD" target="_blank">KOD</a>’s last close, the revised targets imply 25% upside at Jefferies, 61% at LifeSci Capital and 7% at H.C. Wainwright.<h2 class="st-heading-2">How Do Retail Traders Feel About <a class="mention" data-mention="$KOD" data-symbol-id="KOD" href="https://stocktwits.com/symbol/KOD" target="_blank">KOD</a>?</h2>On Stocktwits, retail sentiment for <a class="mention" data-mention="$KOD" data-symbol-id="KOD" href="https://stocktwits.com/symbol/KOD" target="_blank">KOD</a> jumped to ‘extremely bullish’ from ‘neutral’ levels a week ago amid ‘extremely high’ message volume. Followers for the ticker have also risen 9% in a year, indicating healthy retail interest in the stock.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/kod_ss_4e2c18a822.png" alt="kod ss.png" width="642" height="370"><figcaption><a class="mention" data-mention="$KOD" data-symbol-id="KOD" href="https://stocktwits.com/symbol/KOD" target="_blank">KOD</a> sentiment and message volume as of September 28 | Source: Stocktwits</figcaption></figure>One bullish user&nbsp;<a href="https://stocktwits.com/FetchDog/message/665283498">said</a>, “<a class="mention" data-mention="$KOD" data-symbol-id="KOD" href="https://stocktwits.com/symbol/KOD" target="_blank">$KOD</a> My GUESS is an offering at $75 per share to raise $600 million. Probably tomorrow- it takes time to find Daddys with $600 million.”<stembedurl>https://stocktwits.com/FetchDog/message/665283498</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/tahloolaaa/message/665292156">said</a>, “<a class="mention" data-mention="$KOD" data-symbol-id="KOD" href="https://stocktwits.com/symbol/KOD" target="_blank">$KOD</a> This is far superior to eyelea and faricimab.&nbsp; Take a look at what those drugs are doing annually.”<stembedurl>https://stocktwits.com/tahloolaaa/message/665292156</stembedurl><a class="mention" data-mention="$KOD" data-symbol-id="KOD" href="https://stocktwits.com/symbol/KOD" target="_blank">KOD</a> stock has surged 222% year to date.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/asts-stock-change-of-control-payout-plan-ceo-senior-execs-buyout-buzz/cZMmkiMRBX0">ASTS Stock Rises Overnight: Change-Of-Control Payout Plan For CEO, Senior Execs Fuels Buyout Buzz&nbsp;</a>

In this photo illustration, the Kodiak Sciences logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

KOD Stock Cracks September’s Top 5 Biotech Gainers On Eye Drug Win — But ‘Pharma Bro’ Shkreli Says It ‘Still Sucks’

GRAIL Inc.

iShares Biotechnology ETF

Iovance Biotherapeutics Inc

Kodiak Sciences Inc

Moderna Inc

PDS Biotechnology Corporation

Regeneron Pharmaceuticals, Inc.

SPDR S&P Biotech ETF

Health Care Select Sector SPDR Fund

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$3.09
Prev Close	$3.34
Open	$3.34
Dividend Yield	0.00%
50-Day Moving Average	$2.55
Beta	1.26
Avg. Volume	1.53M
PE Ratio	-0.44

52-Week High	$5.96
52-Week Low	$0.92
Market Capitalization	$474.57M
EPS (Annual)	-$21.58
Price to Book	36.20
Revenue Per Employee	$0.00

Feed

News

Sentiment

Fundamentals

Info

INDP Fundamentals